Cladribine Tablets Mode of Action, Learning from the Pandemic: A Narrative Review
Tóm tắt
Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system, characterized by chronic, inflammatory, demyelinating, and neurodegenerative processes. MS management relies on disease-modifying drugs that suppress/modulate the immune system. Cladribine tablets (CladT) have been approved by different health authorities for patients with various forms of relapsing MS. The drug has been demonstrated to deplete CD4+ and CD8+ T-cells, with a higher effect described in the former, and to decrease total CD19+, CD20+, and naive B-cell counts. COVID-19 is expected to become endemic, suggesting its potential infection risk for immuno-compromised patients, including MS patients treated with disease-modifying drugs. We report here the available data on disease-modifying drug-treated-MS patients and COVID-19 infection and vaccination, with a focus on CladT. MS patients treated with CladT are not at higher risk of developing severe COVID-19. While anti-SARS-CoV-2 vaccination is recommended in all MS patients with guidelines addressing vaccination timing according to the different disease-modifying drugs, no vaccination timing restrictions seem to be necessary for cladribine, based on its mechanism of action and available evidence. Published data suggest that CladT treatment does not impact the production of anti-SARS-CoV-2 antibodies after COVID-19 vaccination, possibly due to its relative sparing effect on naïve B-cells and the rapid B-cell reconstitution following treatment. Slightly lower specific T-cell responses are likely not impacting the risk of breakthrough COVID-19. It could be stated that cladribine’s transient effect on innate immune cells likely contributes to maintaining an adequate first line of defense against the SARS-CoV-2 virus.
Tài liệu tham khảo
Filippi M, Bar-Or A, Piehl F, et al. Multiple sclerosis. Nat Rev Dis Primers. 2018;4(1):43. https://doi.org/10.1038/s41572-018-0041-4.
Rammohan K, Coyle PK, Sylvester E, et al. The development of cladribine tablets for the treatment of multiple sclerosis: a comprehensive review. Drugs. 2020;80(18):1901–28. https://doi.org/10.1007/s40265-020-01422-9.
Sasvari-Szekely M, Piroth Z, Kazimierczuk Z, Staub M. A novel effect of the new antileukemic drug, 2-chloro-2’-deoxyadenosine, in human lymphocytes. Biochem Biophys Res Commun. 1994;203(3):1378–84. https://doi.org/10.1006/bbrc.1994.2337.
Leist TP, Weissert R. Cladribine: mode of action and implications for treatment of multiple sclerosis. Clin Neuropharmacol. 2011;34(1):28–35. https://doi.org/10.1097/WNF.0b013e318204cd90.
Carlini F, Ivaldi F, Gualandi F, et al. Different susceptibility of T and B cells to cladribine depends on their levels of deoxycytidine kinase activity linked to activation status. J Neuroimmune Pharmacol. 2021. https://doi.org/10.1007/s11481-021-09994-3.
Stuve O, Soelberg Soerensen P, Leist T, et al. Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers. Ther Adv Neurol Disord. 2019;12:1756286419854986. https://doi.org/10.1177/1756286419854986.
Sellner J, Rommer PS. Multiple sclerosis and SARS-CoV-2 vaccination: considerations for immune-depleting therapies. Vaccines (Basel). 2021;9(2):99. https://doi.org/10.3390/vaccines9020099.
Moser T, Schwenker K, Seiberl M, et al. Long-term peripheral immune cell profiling reveals further targets of oral cladribine in MS. Ann Clin Transl Neurol. 2020;7(11):2199–212. https://doi.org/10.1002/acn3.51206.
Comi G, Cook S, Giovannoni G, et al. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Mult Scler Relat Disord. 2019;29:168–74. https://doi.org/10.1016/j.msard.2019.01.038.
Wiendl H, Schmierer K, Hodgkinson S, et al. Specific patterns of immune cell dynamics may explain the early onset and prolonged efficacy of cladribine tablets: a MAGNIFY-MS substudy. Neurol Neuroimmunol Neuroinflamm. 2023. https://doi.org/10.1212/NXI.0000000000200048.
Soldan SS, Lieberman PM. Epstein-Barr virus and multiple sclerosis. Nat Rev Microbiol. 2023;21(1):51–64. https://doi.org/10.1038/s41579-022-00770-5.
Bjornevik K, Cortese M, Healy BC, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022;375(6578):296–301. https://doi.org/10.1126/science.abj8222.
Dyer Z, Tscharke D, Sutton I, Massey J. From bedside to bench: how existing therapies inform the relationship between Epstein-Barr virus and multiple sclerosis. Clin Transl Immunology. 2023;12(2): e1437. https://doi.org/10.1002/cti2.1437.
Moser T, O’Sullivan C, Puttinger C, et al. Pre-existing humoral immunological memory is retained in patients with multiple sclerosis receiving cladribine therapy. Biomedicines. 2021. https://doi.org/10.3390/biomedicines9111584.
Wiendl H, Schmierer K, Hodgkinson S, et al. Characterization of peripheral immune cell dynamics and repopulation patterns in the first 12 months of cladribine tablets treatment: MAGNIFY-MS study (2235). Neurology. 2021;96(15 Supplement):2235.
Mathiesen CBK, Rudjord-Levann AM, Gad M, Larsen J, Sellebjerg F, Pedersen AE. Cladribine inhibits secretion of pro-inflammatory cytokines and phagocytosis in human monocyte-derived M1 macrophages in-vitro. Int Immunopharmacol. 2021;91: 107270. https://doi.org/10.1016/j.intimp.2020.107270.
Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416–26. https://doi.org/10.1056/NEJMoa0902533.
Moser T, Ziemssen T, Sellner J. Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety. Wien Med Wochenschr. 2022;172(15–16):365–72. https://doi.org/10.1007/s10354-022-00931-4.
Golshani M, Hrdy J. Multiple sclerosis patients and disease modifying therapies: impact on immune responses against COVID-19 and SARS-CoV-2 vaccination. Vaccines (Basel). 2022. https://doi.org/10.3390/vaccines10020279.
Harvey WT, Carabelli AM, Jackson B, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19(7):409–24. https://doi.org/10.1038/s41579-021-00573-0.
Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184(4):861–80. https://doi.org/10.1016/j.cell.2021.01.007.
Ortiz-Prado E, Simbana-Rivera K, Gomez-Barreno L, et al. Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the coronavirus disease 2019 (COVID-19), a comprehensive literature review. Diagn Microbiol Infect Dis. 2020;98(1): 115094. https://doi.org/10.1016/j.diagmicrobio.2020.115094.
Koelle K, Martin MA, Antia R, Lopman B, Dean NE. The changing epidemiology of SARS-CoV-2. Science. 2022;375(6585):1116–21. https://doi.org/10.1126/science.abm4915.
Siddiqi HK, Libby P, Ridker PM. COVID-19 - a vascular disease. Trends Cardiovasc Med. 2021;31(1):1–5. https://doi.org/10.1016/j.tcm.2020.10.005.
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5.
Goumenou M, Sarigiannis D, Tsatsakis A, et al. COVID19 in northern Italy: an integrative overview of factors possibly influencing the sharp increase of the outbreak (Review). Mol Med Rep. 2020;22(1):20–32. https://doi.org/10.3892/mmr.2020.11079.
(CDC) CfDCaP. Available online: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/groups-at-higher-risk.html. Accessed Oct 2020.
Merad M, Blish CA, Sallusto F, Iwasaki A. The immunology and immunopathology of COVID-19. Science. 2022;375(6585):1122–7. https://doi.org/10.1126/science.abm8108.
Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T Cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181(7):1489-501.e15. https://doi.org/10.1016/j.cell.2020.05.015.
Zohar T, Alter G. Dissecting antibody-mediated protection against SARS-CoV-2. Nat Rev Immunol. 2020;20(7):392–4. https://doi.org/10.1038/s41577-020-0359-5.
Kuri-Cervantes L, Pampena MB, Meng W, et al. Comprehensive mapping of immune perturbations associated with severe COVID-19. Sci Immunol. 2020. https://doi.org/10.1126/sciimmunol.abd7114.
Oberfeld B, Achanta A, Carpenter K, et al. SnapShot: COVID-19. Cell. 2020;181(4):954-e1. https://doi.org/10.1016/j.cell.2020.04.013.
Park A, Iwasaki A. Type I and type III interferons - induction, signaling, evasion, and application to combat COVID-19. Cell Host Microbe. 2020;27(6):870–8. https://doi.org/10.1016/j.chom.2020.05.008.
Zhu L, Yang P, Zhao Y, et al. Single-cell sequencing of peripheral mononuclear cells reveals distinct immune response landscapes of COVID-19 and influenza patients. Immunity. 2020;53(3):685-96.e3. https://doi.org/10.1016/j.immuni.2020.07.009.
Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KRW, Pollard AJ. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis. 2021;21(2):e26–35. https://doi.org/10.1016/S1473-3099(20)30773-8.
Pascual-Iglesias A, Canton J, Ortega-Prieto AM, Jimenez-Guardeno JM, Regla-Nava JA. An overview of vaccines against SARS-CoV-2 in the COVID-19 pandemic era. Pathogens. 2021. https://doi.org/10.3390/pathogens10081030.
Weiskopf D, Schmitz KS, Raadsen MP, et al. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. Sci Immunol. 2020. https://doi.org/10.1126/sciimmunol.abd2071.
Sun Y, Zou Y, Wang H, Cui G, Yu Z, Ren Z. Immune response induced by novel coronavirus infection. Front Cell Infect Microbiol. 2022;12: 988604. https://doi.org/10.3389/fcimb.2022.988604.
Persson R, Lee S, Ulcickas Yood M, et al. Infections in patients diagnosed with multiple sclerosis: a multi-database study. Mult Scler Relat Disord. 2020;41: 101982. https://doi.org/10.1016/j.msard.2020.101982.
Wijnands JM, Kingwell E, Zhu F, et al. Infection-related health care utilization among people with and without multiple sclerosis. Mult Scler. 2017;23(11):1506–16. https://doi.org/10.1177/1352458516681198.
Laroni A, Schiavetti I, Sormani MP, Uccelli A. COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments. Mult Scler. 2021;27(14):2126–36. https://doi.org/10.1177/1352458520971817.
Louapre C, Collongues N, Stankoff B, et al. Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol. 2020;77(9):1079–88. https://doi.org/10.1001/jamaneurol.2020.2581.
Sormani MP, De Rossi N, Schiavetti I, et al. Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol. 2021;89(4):780–9. https://doi.org/10.1002/ana.26028.
Simpson-Yap S, De Brouwer E, Kalincik T, et al. Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis. Neurology. 2021;97(19):e1870–85. https://doi.org/10.1212/WNL.0000000000012753.
Mohn N, Konen FF, Pul R, et al. Experience in multiple sclerosis patients with COVID-19 and disease-modifying therapies: a review of 873 published cases. J Clin Med. 2020. https://doi.org/10.3390/jcm9124067.
Iaffaldano P, Lucisano G, Manni A, et al. Risk of getting COVID-19 in people with multiple sclerosis: a case-control study. Neurol Neuroimmunol Neuroinflamm. 2022. https://doi.org/10.1212/NXI.0000000000001141.
Sormani MP, Schiavetti I, Carmisciano L, et al. COVID-19 severity in multiple sclerosis: putting data into context. Neurol Neuroimmunol Neuroinflamm. 2022. https://doi.org/10.1212/NXI.0000000000001105.
Preziosa P, Rocca MA, Nozzolillo A, Moiola L, Filippi M. COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience. J Neurol. 2021;268(8):2697–9. https://doi.org/10.1007/s00415-020-10309-4.
Celius EG. Normal antibody response after COVID-19 during treatment with cladribine. Mult Scler Relat Disord. 2020;46: 102476. https://doi.org/10.1016/j.msard.2020.102476.
De Angelis M, Petracca M, Lanzillo R, Brescia Morra V, Moccia M. Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: two cases and implications for clinical practice. Mult Scler Relat Disord. 2020;45: 102452. https://doi.org/10.1016/j.msard.2020.102452.
Haham N, Vaknin-Dembinsky A. COVID-19 in Cladribine-treated patient with multiple sclerosis. J Neuroimmunol. 2021;359: 577690. https://doi.org/10.1016/j.jneuroim.2021.577690.
Gelibter S, Orrico M, Filippi M, Moiola L. COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: implication for vaccination program? Mult Scler Relat Disord. 2021;49: 102775. https://doi.org/10.1016/j.msard.2021.102775.
Jack D, Damian D, Nolting A, Galazka A. COVID-19 in patients with multiple sclerosis treated with cladribine tablets: an update. Mult Scler Relat Disord. 2021;51: 102929. https://doi.org/10.1016/j.msard.2021.102929.
Barzegar M, Mirmosayyeb O, Gajarzadeh M, et al. COVID-19 among patients with multiple sclerosis: a systematic review. Neurol Neuroimmunol Neuroinflamm. 2021. https://doi.org/10.1212/NXI.0000000000001001.
Albanese A, Sormani MP, Gattorno G, Schiavetti I. COVID-19 severity among patients with multiple sclerosis treated with cladribine: a systematic review and meta-analysis. Mult Scler Relat Disord. 2022;68: 104156. https://doi.org/10.1016/j.msard.2022.104156.
Dos Santos WG. Impact of virus genetic variability and host immunity for the success of COVID-19 vaccines. Biomed Pharmacother. 2021;136: 111272. https://doi.org/10.1016/j.biopha.2021.111272.
Pritchard E, Matthews PC, Stoesser N, et al. Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. Nat Med. 2021;27(8):1370–8. https://doi.org/10.1038/s41591-021-01410-w.
Achiron A, Dolev M, Menascu S, et al. COVID-19 vaccination in patients with multiple sclerosis: what we have learnt by February 2021. Mult Scler. 2021;27(6):864–70. https://doi.org/10.1177/13524585211003476.
Di Filippo M, Cordioli C, Malucchi S, et al. mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2022;93(4):448–50. https://doi.org/10.1136/jnnp-2021-327200.
Achiron A, Mandel M, Dreyer-Alster S, et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. 2021;14:17562864211012836. https://doi.org/10.1177/17562864211012835.
Apostolidis SA, Kakara M, Painter MM, et al. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med. 2021;27(11):1990–2001. https://doi.org/10.1038/s41591-021-01507-2.
Schiavetti I, Barcellini L, Lapucci C, et al. CD19+ B cell values predict the increase of anti-SARS CoV2 antibodies in fingolimod-treated and COVID-19-vaccinated patients with multiple sclerosis. Mult Scler Relat Disord. 2022;70: 104494. https://doi.org/10.1016/j.msard.2022.104494.
Sormani MP, Inglese M, Schiavetti I, et al. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. EBioMedicine. 2021;72: 103581. https://doi.org/10.1016/j.ebiom.2021.103581.
Tallantyre EC, Vickaryous N, Anderson V, et al. COVID-19 vaccine response in people with multiple sclerosis. Ann Neurol. 2022;91(1):89–100. https://doi.org/10.1002/ana.26251.
Brill L, Rechtman A, Zveik O, et al. Effect of cladribine on COVID-19 serology responses following two doses of the BNT162b2 mRNA vaccine in patients with multiple sclerosis. Mult Scler Relat Disord. 2022;57: 103343. https://doi.org/10.1016/j.msard.2021.103343.
Capone F, Lucchini M, Ferraro E, et al. Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies. Neurotherapeutics. 2021. https://doi.org/10.1007/s13311-021-01165-9.
Bock H, Juretzek T, Handreka R, et al. Humoral and cellular immune responses to SARS CoV-2 vaccination in people with multiple sclerosis and NMOSD patients receiving immunomodulatory treatments. Mult Scler Relat Disord. 2022;59: 103554. https://doi.org/10.1016/j.msard.2022.103554.
Tortorella C, Aiello A, Gasperini C, et al. Humoral- and T-cell-specific immune responses to SARS-CoV-2 mRNA vaccination in patients with MS using different disease-modifying therapies. Neurology. 2022;98(5):e541–54. https://doi.org/10.1212/WNL.0000000000013108.
Drulovic J, Ivanovic J, Martinovic V, et al. Humoral response to SARS-CoV-2 COVID-19 vaccines in patients with multiple sclerosis treated with immune reconstitution therapies. Mult Scler Relat Disord. 2021;54: 103150. https://doi.org/10.1016/j.msard.2021.103150.
Aiello A, Coppola A, Ruggieri S, et al. Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies. J Neurol Neurosurg Psychiatry. 2022. https://doi.org/10.1136/jnnp-2022-330175.
Grothe C, Steffen F, Bittner S. Humoral immune response and lymphocyte levels after complete vaccination against COVID-19 in a cohort of multiple sclerosis patients treated with cladribine tablets. J Cent Nerv Syst Dis. 2021;13:11795735211060118. https://doi.org/10.1177/11795735211060118.
Milo R, Staun-Ram E, Karussis D, et al. Humoral and cellular immune responses to SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis: an Israeli multi-center experience following 3 vaccine doses. Front Immunol. 2022;13: 868915. https://doi.org/10.3389/fimmu.2022.868915.
Schiavetti I, Cordioli C, Stromillo ML, et al. Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies. Mult Scler. 2022;28(13):2106–11. https://doi.org/10.1177/13524585221102918.
Sormani MP, Schiavetti I, Inglese M, et al. Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy. EBioMedicine. 2022;80: 104042. https://doi.org/10.1016/j.ebiom.2022.104042.
Holroyd KB, Healy BC, Conway S, et al. Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: immune profiles and clinical outcomes. Mult Scler Relat Disord. 2022;67: 104079. https://doi.org/10.1016/j.msard.2022.104079.
MS International Federation. MS tcavugahwmont-c-a-m-w-y-n-t-k. 2020. https://doi.org/10.1016/j.devcel.2019.05.023.
NMSC-VGfPLwMhwnoc-c--im-s-a-cc--v-g. 2021. https://doi.org/10.1039/c9sc00341j. Accessed Oct 05 2021.
Rieckmann P, Centonze D, Giovannoni G, et al. Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice. Ther Adv Neurol Disord. 2021;14:17562864211058298. https://doi.org/10.1177/17562864211058298.
Moiola L, Barcella V, Benatti S, et al. The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: a Delphi consensus statement. Mult Scler. 2021;27(3):331–46. https://doi.org/10.1177/1352458520952311.
Baker D, Herrod SS, Alvarez-Gonzalez C, Zalewski L, Albor C, Schmierer K. Both cladribine and alemtuzumab may effect MS via B-cell depletion. Neurol Neuroimmunol Neuroinflamm. 2017;4(4): e360. https://doi.org/10.1212/nxi.0000000000000360.
Ceronie B, Jacobs BM, Baker D, et al. Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells. J Neurol. 2018;265(5):1199–209. https://doi.org/10.1007/s00415-018-8830-y.
Mariottini A, Bertozzi A, Marchi L, et al. Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis. J Neurol. 2022;269(6):2840–7. https://doi.org/10.1007/s00415-022-11003-3.
Disanto G, Sacco R, Bernasconi E, et al. Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing With Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis. JAMA Neurol. 2021;78(12):1529–31. https://doi.org/10.1001/jamaneurol.2021.3609.